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Design: Descriptive, prospective, repeated measures.
Setting: An interdisciplinary breast clinic at a universityaffiliated comprehensive cancer center in the United States.
Sample: 49 women with newly diagnosed breast cancer and undergoing adjuvant therapy who participated in a stress management intervention.
Methods: Relaxation practice was assessed twice a month for 10 months with immune measurements (e.g., natural killer cell activity; lymphocyte proliferation; interferon [IFN]-g; interleukin [IL]-2, -4, -6, and -10) at the beginning and end of 10-month practice.
Main Research Variables:
Relaxation practice (representing the concepts of stress and adherence), relaxation technique, and immune response.
Findings: After adjusting for covariates, the extent of relaxation practice significantly contributed to the variance of natural killer cell activity, lymphocyte proliferation, IL-4, and IL-10 responses in a positive direction; the higher the relaxation practice, the higher the immune responses. In comparison, IFN-g, IL-2, and IL-6 responses were not affected. The deep-breathing method was most preferred by participants, followed by progressive relaxation and imagination or visualization. The mean weekly frequency of relaxation practice was 5.29 (SD = 3.35), and the mean duration of relaxation practice was 19.16 (SD = 10.81) minutes per session. Although most patients experience a gradual decline of stress over time, some continue to experience high levels of stress for years, even after the successful completion of cancer treatment (Bleiker et al., 2000) . Others experience post-traumatic stress disorder precipitated by a cancer diagnosis (Kangas, Henry, & Bryant, 2002) . In addition, in a study by Palmer, Kagee, Coyne, and DeMichele (2004), 41% of women with breast cancer reported significant fear, helplessness, or horror related to their experience with cancer.
Stress can lead to a variety of adverse health outcomes, including greater upper respiratory tract infections and periodontal diseases, accelerated aging, and increased cardiovascular diseases, in diverse populations (Cohen, 1995; Kiecolt-Glaser, McGuire, Robles, & Glaser, 2002a , 2002b . The well-controlled studies of animal models of cancer also showed that stress decreased the efficacy of or resistance to chemotherapeutic agents (Kerr, Hundal, Silva, Emerman, & Weinberg, 2001; Su et al., 2005) , and high stress was associated with low physical and psychological quality of life in women with breast cancer (Golden-Kreutz et al., 2005; Härtl et al., 2010; Luecken & Compas, 2002; Yang et al., 2008) . In addition, women with metastatic or recurrent breast cancer who had experienced one or more highly stressful or traumatic events in their lives showed a significantly shorter disease-free interval (median = 31 months) compared with women who had not experienced such events (median = 62 months) This material is protected by U.S. copyright law. Unauthorized reproduction or online display is prohibited. To purchase quantity reprints, e-mail reprints@ons.org. For permission to reproduce multiple copies, e-mail pubpermissions@ons.org.
